Tag: BET

ABBV-744 is a First-in-Class, Orally Active and Selective BET BDII Inhibitor

The proteins of BET (bromodomain and extra-terminal) domain family are epigenetic readers. BET domain family proteins bind acetylated histones through their bromodomains to regulate gene transcription. BET domain family proteins consist of BRD2, BRD3, BRD4 and BRDT. They contain BDI, BDII and the extra-terminal (ET) domain. Interestingly, BDII of...

GSK973 is a Highly Selective BET BD2 Inhibitor

The bromodomain and extra-terminal (BET) family of proteins are epigenetic readers of chromatin. The two tandem bromodomains (BD1 and BD2) of each of the four proteins (BRD2, 3, 4, and T) recognize and bind to specific acetylated-lysine residues of histone tails and non-histone proteins. They play a major role...

NHWD-870 is an Orally Active and Selective BET Bromodomain Inhibitor

Brominedomain can recognize acetylated lysine residues. As the “reader” of lysine acetylation, the bromine domain is responsible for the transduction of signals carried by acetylated lysine residues and transforming them into various normal or abnormal phenotypes. Specifically, the bromine domain-containing proteins have a variety of functions. Besides, it ranges...

CC-90010 is a Reversible and Orally Active BET Inhibitor

Come straight to the point, CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors. The bromodomain and extra-terminal domain (BET) proteins, epigenetic readers, recognize and bind acetylated lysine residues. The BET protein family comprises the ubiquitously expressed...

BETd-260 is a Potent PROTAC BET Degrader

The bromodomain and extra-terminal (BET) family proteins consist of BRD2, BRD3, BRD4, and testis-specific BRDT members. They are epigenetic “readers” and play a key role in the regulation of gene transcription. BET proteins are attractive therapeutic targets for cancer and other human diseases. In this study, BETd-260 is capable...